1. Market Research
  2. > Healthcare
  3. > Diagnostics Market Trends
  4. > A 33-Country Survey of the Cancer Diagnostic Testing Market: Sales Forecasts and Supplier Shares for 40 Tumor Markers--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Competitive Strategies, Opportunities

This report is delivered in 10-15 working days

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding cancer diagnostic testing market, in evaluating emerging opportunities and developing effective business strategies during the next five years.

The report provides granular market segmentation analysis and forecasts for over 40 tumor markers; profiles leading suppliers and recent market entrants with innovative technologies and products; reviews current and emerging assays; reviews current instrumentation; evaluates emerging technologies; and offers specific opportunities and growth strategies for suppliers.

Rationale

The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the worldwide cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion worldwide.

Geographic Coverage

Australia, Austria, Belgium, Bulgaria, Canada, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Japan, Latvia, Lithuania, Malta, Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, Switzerland, UK, US

Business Opportunities and Strategic Recommendations

- Specific new product development opportunities with potentially
significant market appeal during the next five years.

- Design criteria for new products.

- Alternative market penetration strategies.

- Potential market entry barriers and risks.

Over 200 Current and Emerging Cancer Diagnostic Tests

- Oncogenes
- Biochemical Markers
- Growth Factors
- Colony Stimulating Factors
- Hormones
- Immunohistochemical Stains
- Lymphokines

- ACTH, AFP, Beta-2 Microglobulin, CA 15-3/27.29, CA 19-9, CA 125, Calcitonin, Cathepsin, CEA,
Chromogranin, Colon-Specific Antigen, Cytokeratins, Estrogen Receptor, Ferritin, Gastrin, HCG,
Insulin, Interferons, Interleukins, Lymphocyte Subtyping, Neuron-Specific Enolase, Nucleolar,
Occult Blood, Oncogenes, Pancreatic Oncofetal Antigen, Pap Smear, Parathyroid Hormone,
Progesterone Receptor, Prostatic Acid Phosphatase, Prostatic Specific Antigen, S-100 Protein,
Serotonin, Sialic Acid, Squamous Cell Carcinoma Ag, TDT, Thymidine Kinase, Thyroglobulin,
Tissue Polypeptide Antigen, and others.

Supplier Shares, Sales and Volume Forecasts

- Sales and market shares of major cancer diagnostic product suppliers
in major countries by individual test.

- Five-year test volume and sales forecasts
for major cancer diagnostic assays.

Instrumentation Review

- Analysis of major molecular diagnostic and immunodiagnostic analyzers
used for cancer testing, including their operating characteristics,
features and selling prices.

Technology Assessment
- Assessment of latest technologies
and their potential applications for cancer diagnostic testing.
- Review of competing/complementing technologies.
- Companies, universities and research centers developing new cancer diagnostic tests
and detection technologies.

Competitive Strategies
- Strategic assessments of major suppliers
and start-up firms developing innovative cancer diagnostic
technologies and products, including their sales,
product portfolios, marketing tactics, collaborative
arrangements, and new products in R&D.
- The companies analyzed in the report include:
- Abbott
- AdnaGen
- Agilent Technologies
- Applied Gene Technologies
- Arca Biopharma
- Beckman Coulter/Danaher
- Becton Dickinson
- Biomedical Diagnostics
- bioMerieux
- Bio-Rad
- CellSearch
- Cepheid
- Correlogic Systems/Vermillion
- Decode Genetics
- Diadexus
- Diagnocure
- DiaSorin
- Eiken Chemical
- Elitech Group
- Enterix/Clinical Genomics
- Enzo Biochem
- Epigenomics
- Exact Sciences
- Fujirebio
- Guided Therapeutics
- Hologic/Gen-Probe
- Kreatech/Leica
- Kyowa Medex
- Mackay Life Sciences
- Myriad Genetics
- OncoLab
- Ortho-Clinical Diagnostics
- Panacea Pharmaceuticals
- Polartechnics
- Polymedco
- PreMD
- Qiagen
- Quest Diagnostics
- Radient Pharmaceuticals
- Roche
- Scienion
- Sequenom
- Siemens Healthcare
- Takara Bio
- Targeted Diagnostics & Therapeutics
- Thermo Fisher/Affymetrix
- Tosoh
- Veridex
- Wako Pure Chemicals
- Wallac/PE
- Zilla/Alere
Contains 1,300 pages and 500 tables.

Table Of Contents

A 33-Country Survey of the Cancer Diagnostic Testing Market: Sales Forecasts and Supplier Shares for 40 Tumor Markers--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Competitive Strategies, Opportunities
I. Introduction
II. Worldwide Market Overview
III. Major Product Development Opportunities
A. Reagent Kits and Test Systems/Panels
B. Instrumentation
C. Computers, Software and Automation
D. Auxiliary Products
IV. Design Criteria for Decentralized Testing Products
V. Alternative Market Penetration Strategies
A. Internal Development
B. Collaborative Arrangements
C. University Contracts
D. Distribution Strategies
VI. Potential Market Entry Barriers and Risks
A. Market Maturity
B. Cost Containment
C. Competition
D. Technological Edge and Limitations
E. Patent Protection
F. Regulatory Constraints
G. Decentralized Testing Market Challenges
VII. Worldwide Market and Technology Overview
A. Cancer Statistics and Etiology
1. Breast Cancer
2. Lung Cancer
3. Colon and Rectum Cancer
4. Prostate Cancer
5. Stomach Cancer
6. Leukemia
7. Lymphoma
8. Oral Cancer
9. Skin Cancer
10. Uterine Cancer
11. Ovarian Cancer
12. Bladder Cancer

B. Major Current and Emerging Cancer Diagnostic Tests
1. Introduction
2. Tumor Marker Classification
3. ACTH
4. Alpha-Fetoprotein (AFP)
5. Beta-2 Microglobulin
6. CA 15-3/27.29
7. CA 19-9
8. CA-125
9. Calcitonin
10. Carcinoembrionic Antigen (CEA)
11. Estrogen and Progesterone Receptors
12. Ferritin
13. Gastrin
14. Human Chorionic Gonadotropin (HCG)
15. Insulin
16. NSE
17. Occult Blood
18. PAP Smear/HPV
19. Prostatic Acid Phosphatase (PAP)
20. Prostate-Specific Antigen (PSA)
21. Squamous Cell Carcinoma Antigen (SCC)
22. T and B Lymphocytes
23. TdT
24. Thyroglobulin
25. Tissue Polypeptide Antigen (TPA)
26. Biochemical Tumor Markers
27. Oncogenes
- Abl/abl-bcr
- AIB1
- BCL-2
- BRCA1
- CD44
- C-fos
- C-myb
- C-myc
- CYP-17
- Erb-B
- HPC1
- N-myc
- P40
- P51
- P53
- PIK3CA
- PTI-1
- Ras
- Reg

- Sis
- Src
28. Polypeptide Growth Factors
- Basic Fibroblast Growth Factor
- Beta-TGF
- Cachectin (TNT)
- Calmodulin
- ECFR
- Nerve Growth Factor (NGF)
- Epidermal Growth Factor (EGF)
- Ornithine Decarboxylase
- Transferrin
- Transforming Growth Factor-Alpha
29. Ectopic Hormones
30. Colony Stimulating Factors
31. Lymphokines
- Alpha-Interferon
- B Cell Growth Factors
- B Cell Growth Factor (BCGF)
- Gamma-Interferon
- Interleukin-1 (IL-1)
- Macrophage Activating Factor
32. Immunohistochemical Stains
33. Emerging Tumor Markers
- N-Acetylglucosamine
- Actin
- Alpha-Actin
- Antineuronal Antibodies
- 7B2
- B72.3
- Bax
- BCD-F9
- BLCA-4
- Blood Group Antigens A,B,H
- CA 50
- CA 72-4/TAG-72
- CA 195
- CA-242
- CA-549
- CAM 26
- CAR-3
- Cathepsin-D
- Chromogranin A and B
- Cluster 1 Antigen
- Cluster-5/5A Antigen
- CTA
- CU18
- DR-70

- DU-PAN-2
- Endometrial Bleeding Associated Factor
- Endostatin
- Epithelial Membrane Antigen
- Feulgen Hydrolysis
- Fibronectin
- FSH
- (1->3)-L-fucosyltransferase
- Gastrin-Releasing Peptide (GRP)
- GDCFP-15
- Glucagon
- Glycoamines
- H23
- Her-2
- Human Carcinoma Antigen
- HPA
- HSP27
- Intermediate Filaments
- Cytokeratins/CK18/Cyfra 21-1
- Desmin
- Gliofibrillary Acid Protein
- Neurofilaments
- Vimentin
- KA 93
- Kinases
- KP16D3
- LAI
- Leukocyte Common Antigen
- Lewis Antigens
- Lysophosphatidic Acid (LPA)
- Ma 695/Ma 552
- MABDF3
- MAG
- ME1
- Minactivin
- MN/CA9
- MSA
- Mucin Cancer Antigen (MCA)
- Multiple Tumor Suppressor 1
- Myosin
- NEA-130
- NMP22
- OA-519
- Opioid Peptides
- P-glycoprotein
- Pancreatic Oncofetal Antigen (POA)
- Placental Lactogen
- PR92

- Proliferative Index, Ki-67
- Px
- RB Inactivation/Deletion
- Ret
- SCCL 175
- Selectin
- Sialic Acid
- Sialyl SSEA-1/SLX
- SN10
- Somatostatin
- TA-90
- TABA
- Tachykinin
- TAG 12
- TPS
- Troponin
- Tubulin
- VCAM
- VEGF
- Villen
C. Cancer Diagnostic Testing Instrumentation Review and Market Needs
D. Current and Emerging Cancer Diagnostic Technologies
1. Monoclonal and Polyclonal Antibodies
2. Immunoassays
3. Molecular Diagnostics
4. Chromosome Analysis
a. Chronic Myelogenous Leukemia (CML)
b. Acute Myeloid Leukemia (AML)
c. Acute Lymphoblastic Leukemia (ALL)
d. Malignant Lymphomas Lymphoid Malignancies
e. Chronic Lymphocytic Leukemia (CLL)
f. Solid Cancers
g. Chromosomal Translocation and Oncogenes
5. Artificial Intelligence
6. Flow Cytometry
7. Two Dimensional Gel Electrophoresis (2-DGE)
8. Biosensors
9. Competing/Complementing Technologies
E. Personal Testing
VIII. Country Market Analyses: Test Volume and Sales Forecasts, Supplier Shares
- Australia
- Austria

- Belgium
- Bulgaria
- Canada
- Cyprus
- Czech Republic
- Denmark
- Estonia
- Finland
- France
- Germany
- Greece
- Hungary
- Iceland
- Ireland
- Italy
- Japan
- Latvia
- Lithuania
- Malta
- Netherlands
- Norway
- Poland
- Portugal
- Romania
- Slovakia
- Slovenia
- Spain
- Sweden
- Switzerland
- UK
- USA
IX. Competitive Profiles
- Abbott
- AdnaGen/Alere
- Agilent Technologies
- Applied Gene Technologies
- Arca Biopharma
- Beckman Coulter/Danaher
- Becton Dickinson
- Biomedical Diagnostics
- bioMerieux
- Bio-Rad
- CellSearch
- Cepheid
- Correlogic Systems/Vermillion
- Decode Genetics

- Diadexus
- Diagnocure
- Diasorin
- Eiken Chemical
- Elitech Group
- Enterix
- Enzo Biochem
- Epigenomics
- Exact Sciences
- Fujirebio
- Guided Therapeutics
- Hologic/Gen-Probe
- Kreatech/Leica
- Kyowa Medex
- Mackay Life Sciences
- Myriad Genetics
- OncoLab
- Ortho-Clinical Diagnostics
- Panacea Pharmaceuticals
- Polartechnics
- Polymedco
- PreMD
- Qiagen
- Quest Diagnostics
- Radient Pharmaceuticals
- Roche
- Scienion
- Sequenom
- Siemens Healthcare
- Takara Bio
- Targeted Diagnostics and Therapeutics
- Tosoh
- Thermo
- Veridex
- Wako Pure Chemicals
- Wallac/PE
- Zila
X. Appendix: Major Universities and Research
Centers Developing Cancer Diagnostic
Technologies and Applications

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Cancer Diagnostics 2020: Supplier Shares and Strategies, Country Segment Forecasts, Technology Trends, Emerging Opportunities--Tumor Markers, Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains

Cancer Diagnostics 2020: Supplier Shares and Strategies, Country Segment Forecasts, Technology Trends, Emerging Opportunities--Tumor Markers, Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains

  • $ 21100
  • Industry report
  • October 2016
  • by Venture Planning Group

Complete report $34,750.  DataPack (test volumes, sales forecasts, supplier shares) $21,100.  The report is available by country, section, market segment, and can be custom-tailored to your specific ...

Tumor Markers: Supplier Shares by Test, Competitive Strategies, Country Volume and Sales Segment Forecasts, Technology Trends, Instrumentation Review,  Emerging Opportunities--France, Germany, Italy, Japan, Spain, UK, US

Tumor Markers: Supplier Shares by Test, Competitive Strategies, Country Volume and Sales Segment Forecasts, Technology Trends, Instrumentation Review, Emerging Opportunities--France, Germany, Italy, Japan, Spain, UK, US

  • $ 21100
  • Industry report
  • October 2016
  • by Venture Planning Group

Complete report $34,750.  DataPack (test volumes, sales forecasts, supplier shares) $21,100.  The report is available by country, section, market segment, and can be custom-tailored to your specific ...

Europe Tumor Marker Diagnostic Testing Market: Future Horizons and Growth Strategies--Instrument and Reagents Supplier Shares, Country Segment Forecasts, Competitive Intelligence, Opportunities

Europe Tumor Marker Diagnostic Testing Market: Future Horizons and Growth Strategies--Instrument and Reagents Supplier Shares, Country Segment Forecasts, Competitive Intelligence, Opportunities

  • $ 12800
  • Industry report
  • August 2016
  • by Venture Planning Group

This unique report provides information not available from any other published source, including volume, sales, and leading supplier shares by test. This comprehensive five-country report identifies and ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.